• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.

    4/17/25 6:34:30 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 8)


    ALLURION TECHNOLOGIES, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    02008G201

    (CUSIP Number)


    Roderick Wong, M.D.
    RTW Investments, LP, 40 10th Avenue, Floor 7
    New York, NY, 10014
    (646) 597-6980


    Louis Rambo
    Proskauer Rose, LLP, 1001 Pennsylvania Ave, N.W., Suite 600
    Washington, DC, 20004-2533
    (212) 416-6800

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/15/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    02008G201


    1 Name of reporting person

    RTW Investments, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,542,603.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,542,603.00
    11Aggregate amount beneficially owned by each reporting person

    2,542,603.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    34.1 %
    14Type of Reporting Person (See Instructions)

    PN, IA



    SCHEDULE 13D

    CUSIP No.
    02008G201


    1 Name of reporting person

    RTW Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,324,532.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,324,532.00
    11Aggregate amount beneficially owned by each reporting person

    1,324,532.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    17.8 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    02008G201


    1 Name of reporting person

    RTW Innovation Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,027,287.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,027,287.00
    11Aggregate amount beneficially owned by each reporting person

    1,027,287.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    13.8 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP No.
    02008G201


    1 Name of reporting person

    Roderick Wong, M.D.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,542,603.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,542,603.00
    11Aggregate amount beneficially owned by each reporting person

    2,542,603.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    34.1 %
    14Type of Reporting Person (See Instructions)

    IN, HC



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    ALLURION TECHNOLOGIES, INC.
    (c)Address of Issuer's Principal Executive Offices:

    11 Huron Drive, Natick, MASSACHUSETTS , 01760.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) of this Amendment No. 8 is incorporated by reference herein to this Item 3.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) and Item 6 of this Amendment No. 8 is incorporated by reference herein to this Item 4.
    Item 5.Interest in Securities of the Issuer
    (a)
    Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows: The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon (i) 5,963,549 Shares outstanding as of March 24, 2025, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025, and (ii) an additional 1,492,539 Shares issued by the Issuer on April 15, 2025 pursuant to the Conversion Notice (as defined in Item 6). The remaining principal amount of the Notes are subject to a beneficial ownership conversion limitation such that the RTW Funds cannot convert Notes to the extent it would result in the RTW Funds and their affiliates beneficially owning more than 9.99% of the Issuer's Shares, except as described in Item 6 hereof. The Warrants held by the RTW Funds are subject to a Blocker (as defined in Item 4 of Amendment No. 2 to the Schedule 13D), which is currently set at 4.99% and can be increased to 9.99% upon 61 days' prior notice by RTW.
    (b)
    See rows (7) through (10) of the cover page to this Amendment No. 8 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition
    (c)
    On April 16, 2025, the RTW Funds delivered the Conversion Notice to acquire 1,492,539 Shares. Other than as reported herein, the Reporting Persons did not effect any transactions with respect to the Shares during the past sixty (60) days.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    On April 15, 2025, RTW Investments and certain of the RTW Funds entered into the Second Amendment to the Note Purchase Agreement, which amends the Amended Note Purchase Agreement described in Item 4 to Amendment No. 1 to this Schedule 13D. The Second Amendment granted the RTW Funds additional conversion rights as follows, with such additional conversion rights being exempt from the beneficial ownership limitation contained in the Amended Note Purchase Agreement: (i) In the event that the Market Capitalization Condition (as defined in the Second Amendment) has been triggered, the RTW Funds agreed to provide the Company with, and the Company agreed to accept, a conversion notice to convert $5.0 million aggregate principal amount of the Notes at a conversion rate equal to 298.5075 Shares per $1,000 principal amount of Notes, reflecting a floor conversion price of $3.35 per share (the "Floor Conversion Rate") for an aggregate of 1,492,539 Shares. (ii) In the event that the Market Capitalization Condition is triggered, the RTW Funds may provide a conversion notice to the Company to convert up to $5.0 million aggregate principal amount of the Notes into Shares at a conversion rate mutually agreed upon by the RTW Funds and the Company, with such conversion rate not being less than the Floor Conversion Rate. The Company may accept or reject such notice in its sole discretion. (iii) At any time, the RTW Funds may provide to the Company a notice to convert up to $5 million aggregate principal amount of the Notes into Shares at a rate equal to the lesser of (i) the quotient of $1,000 divided by the Daily VWAP (as defined in the Amended Note Purchase Agreement) for the period specified in such notice discounted by 5%, calculated based on the five consecutive trading days ending on the trading day immediately preceding the date of the notice, and (ii) the Floor Conversion Rate (the "5-Day VWAP Conversion Rate"). The Company may accept or reject such notice in its sole discretion. (iv) A maximum of once per month until April 15, 2026, the RTW Funds may provide to the Company a notice to convert up to an additional $1 million aggregate principal amount of the Notes in any 30-day period into Shares at the 5-Day VWAP Conversion Rate. The Company may accept or reject such notice in its sole discretion. If the RTW Funds do not exercise their right to provide such monthly conversion notice for all or a portion of such monthly amount, or if the Company does not accept such notice, the RTW Funds are permitted to include any such unused amount in any subsequent monthly conversion notice. In addition, the parties to the Second Amendment confirmed that the conversion rate applicable to conversions of the Notes pursuant to Section 4.1 of the Amended Note Purchase Agreement will continue to be equal to 24.6920 Shares per $1,000 principal amount. The RTW Funds also agreed that, until the earlier of (i) the effective date of any Fundamental Change or Make-Whole Fundamental Change (each as defined in the Amended Note Purchase Agreement) and (ii) the date on which the RTW Funds and their affiliates collectively hold less than 9.99% of the voting power of the outstanding Shares of the Company, the RTW Funds will, at any meeting of the Company' stockholders, abstain from voting Shares acquired pursuant to the additional conversion rights provided by the Second Amendment (the "Relevant Shares"), or vote the Relevant Shares in proportion to the votes cast on the applicable matter with respect to the Shares beneficially owned by persons other than the RTW Funds or any of their affiliates. On April 16, 2025, the RTW Funds provided the Company with, and the Company accepted, a conversion notice (the "Conversion Notice"), pursuant to which $5.0 million aggregate principal amount of the Notes was converted into 1,492,539 shares. The foregoing description of the Second Amendment to the Note Purchase Agreement is not complete and is qualified in its entirety by reference to the complete text of the Second Amendment to the Note Purchase Agreement, which is filed as Exhibit 99.21 to this Amendment No. 8 to the Schedule 13D and incorporated by reference to this Item 6.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is hereby amendmed and supplemented as follows: Exhibit 99.21 Second Amendment to the Note Purchase Agreement, dated April 15, 2025 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2025).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RTW Investments, LP
     
    Signature:/s/ Roderick Wong, M.D.
    Name/Title:Roderick Wong, M.D., Managing Partner
    Date:04/17/2025
     
    RTW Master Fund, Ltd.
     
    Signature:/s/ Darshan Patel
    Name/Title:Darshan Patel, Director
    Date:04/17/2025
     
    RTW Innovation Master Fund, Ltd.
     
    Signature:/s/ Darshan Patel
    Name/Title:Darshan Patel, Director
    Date:04/17/2025
     
    Roderick Wong, M.D.
     
    Signature:/s/ Roderick Wong, M.D.
    Name/Title:Roderick Wong, M.D.
    Date:04/17/2025
    Get the next $ALUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    SEC Filings

    View All

    SEC Form 144 filed by Allurion Technologies Inc.

    144 - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    12/2/25 3:56:15 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by Allurion Technologies Inc.

    D - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    11/26/25 4:18:44 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Allurion Technologies Inc.

    DEFA14A - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    11/25/25 5:09:14 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

    Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and increased to no greater than 5.0mg over the subsequent 2 months, cons

    11/25/25 9:25:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

    Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone Average weight reduction of 20% at 36 weeks, on par with bariatric surgery and high-dose GLP-1 therapy Improved body composition without adversely affecting muscle mass Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact

    11/20/25 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical's 30-year experience in the Brazilian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss. ProSurg Medical has extensive experience in building high-performing medical networks spanning over 300 hospitals across Brazil with teams that include dietitians, bariatric surgeons, and endoscopic specialists

    11/18/25 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Davin Michael R received a gift of 3,212 shares, sold $4,918 worth of shares (3,212 units at $1.53) and gifted 3,212 shares, decreasing direct ownership by 73% to 1,206 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    12/5/25 7:23:17 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Rtw Investments, Lp was granted 1,856,288 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    11/13/25 5:26:01 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    11/7/25 5:18:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Allurion Technologies with a new price target

    ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    9/6/24 7:25:38 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

    Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

    9/3/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

    Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

    8/20/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

    Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

    6/5/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Financials

    Live finance-specific insights

    View All

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

    Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart Capsule Exchange of outstanding debt for shares of convertible preferred stock would result in Company being debt-free $5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company's financial position as the Company seeks FDA approval Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced it has

    11/11/25 8:45:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    11/6/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:15:52 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care